Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 4/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609237 | 0.84 | LTA4H (0.44) | LTA4HMAPTTSHRSMN1; SMN2MEN1 | |
| SCHEMBL8540552 | 0.84 | LMNA (0.47) | LTA4HMMP1SCN9ALMNAMAPT | |
| SCHEMBL23069186 | 0.76 | CYP19A1 (0.35) | LTA4HLMNATSHRCYP19A1TDP1 | |
| SCHEMBL921837 | 0.76 | LTA4H (0.37) | LTA4HMMP1SCN9ALMNATSHR | |
| SCHEMBL694392 | 0.76 | LMNA (0.62) | LTA4HLMNACYP19A1MAP4K4SMN1; SMN2 | |
| SCHEMBL22061918 | 0.76 | LMNA (0.44) | LTA4HMMP1SCN9ALMNAMAPT | |
| SCHEMBL1680381 | 0.74 | LTA4H (0.67) | LTA4HLMNAMAPTTSHRCYP19A1 | |
| Water SCHEMBL28744175 | 0.74 | LTA4H (0.67) | LTA4HTSHRMEN1KMT2A | |
| SCHEMBL49434 | 0.74 | LTA4H (0.67) | LTA4HTSHRMEN1KMT2A | |
| SCHEMBL10839908 | 0.74 | ALDH1A1 (0.39) | LTA4HMAPTTSHRMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | claimed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | claimed |
| JP-4829123-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-7816365-B2 | Amine derivatives | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| EP-2183239-A1 | SULFONAMIDES AS TRPM8 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2010-05-12 | — | — | EP | claimed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | claimed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | claimed |
| WO-2009012430-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-22 | — | — | WO | claimed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20070112006-A1 | Amine derivatives | MERCK PATENT GMBH (DE) | 2007-05-17 | — | — | US | claimed |
| WO-2005110994-A2 | SUBSTITUTED PYRAZOLYL UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-24 | — | — | WO | claimed |
| WO-2005054246-A2 | AMINE DERIVATIVES HAVING A TYROSINE-KINASE-INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 2005-06-16 | — | — | WO | claimed |
| EP-1423119-A4 | HETEROBICYCLES FKBP-LIGANDS | AGOURON PHARMA (US) | 2005-04-13 | — | — | EP | claimed |
| EP-1423119-A1 | HETEROBICYCLES FKBP-LIGANDS | Agouron Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | claimed |
| US-6482827-B1 | Matrix metalloproteinase inhibitors | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-11-19 | — | — | US | claimed |
| WO-2002089806-A1 | HETEROBICYCLES FKBP-LIGANDS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | claimed |
| EP-0944587-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2002-03-20 | — | — | EP | claimed |
| EP-0925289-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-06-30 | — | — | EP | claimed |
| WO-1999002510-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-01-21 | — | — | WO | claimed |
| US-5840974-A | Metalloproteinase inhibitors | BRITISCH BIOTECH PHARMACEUTICALS, LTD. (GB) | 1998-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112006-A1 | Amine derivatives | TIE1, FLT1, KDR | LTA4H 4630/4885MMP1 3010/4885SCN9A 4089/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | LTA4H 1198/4885MMP1 4838/4885SCN9A 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.